North China Pharmaceutical’s subsidiary’s recombinant tetanus vaccine approved for clinical trials
May 19, 2025
Source: drugdu
98
On May 15, North China Pharmaceutical(600812) announced that its subsidiary Jintan Company recently received the "Drug Clinical Trial Approval Notice" for the recombinant tetanus vaccine (Escherichia coli) approved and issued by the National Medical Products Administration. The acceptance number of the notice is CXSL2500168, the notice number is 2025LP01313, the dosage form is injection, the specification is 30μg/0.5ml/piece, and the approval conclusion shows that the vaccine meets the relevant requirements for drug registration and agrees to conduct clinical trials.
As of April 2025, Jintan's cumulative R&D expenses for this drug are RMB 39.71 million (unaudited). Currently, there is no recombinant tetanus vaccine based on genetic engineering on the market at home and abroad, and Jintan's R&D will fill this market gap.
In the first quarter of 2025, North China Pharmaceutical achieved revenue of 2.574 billion yuan and net profit attributable to shareholders of the parent company of 57.49 million yuan.
https://finance.eastmoney.com/a/202505153405639922.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for the marketing approval of the innovative drug in the field of autoimmune diseases jointly developed with Connect Biopharmaceuticals has been accepted July 10, 2025
- Kanghua Biopharma terminates cooperation in tuberculosis and rabies vaccine research and development July 10, 2025
- Small nucleic acid therapy challenges GLP-1 giants July 10, 2025
- Baili Tianheng BL-B01D1 Update Progress July 10, 2025
- FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema July 10, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
